SCHEMBL607384

SCHEMBL607384

COc1ccc(CN2CCN(CC(O)Cn3c4ccccc4c4cc(Br)ccc43)CC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.82
MAPK1 P28482 3/20 0.82
HTT P42858 3/20 0.82
MAPT P10636 6/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
RAD52 P43351 1/20 0.66
GAA P10253 3/20 0.62
TP53 P04637 5/20 0.55
BAX Q07812 1/20 0.54
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
DNM1 Q05193 2/20 0.52
THRB P10828 1/20 0.50
POLB P06746 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL605724 0.95 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL605725 0.95 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5022683 0.95 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607474 0.91 LMNA (1.00) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL606781 0.89 LMNA (0.64) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5026925 0.89 LMNA (0.64) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607481 0.87 MEN1 (0.67) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607210 0.87 MEN1 (0.69) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607023 0.85 LMNA (0.73) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL6815606 0.85 MEN1 (0.88) LMNAMAPK1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD LMNA 55/4885MAPK1 3036/4885HTT 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.